Get the Stockscreener App
4.02
0.75%
0.03
After Hours:
4.04
0.02
+0.50%
X 4 Pharmaceuticals Inc stock is traded at $4.02, with a volume of 10.48M.
It is up +0.75% in the last 24 hours and up +0.50% over the past month.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
See More
Previous Close:
$3.99
Open:
$3.98
24h Volume:
10.48M
Relative Volume:
18.67
Market Cap:
$379.17M
Revenue:
$9.01M
Net Income/Loss:
$-99.72M
P/E Ratio:
-0.8858
EPS:
-4.5381
Net Cash Flow:
$-92.85M
1W Performance:
-4.74%
1M Performance:
+0.50%
6M Performance:
-10.67%
1Y Performance:
+101.00%
1-Day Range:
$3.98
$4.235
1-Week Range:
$3.92
$4.425
52-Week Range:
$1.35
$4.83
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
Name
X 4 Pharmaceuticals Inc
Sector
Industry
Phone
857-529-8300
Address
61 NORTH BEACON STREET, BOSTON, MA
Compare XFOR vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
4.02 | 379.17M | 9.01M | -99.72M | -92.85M | -4.5381 |
VRTX
Vertex Pharmaceuticals Inc
|
491.34 | 124.70B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
632.90 | 66.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
887.18 | 55.17B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
291.37 | 38.90B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
182.08 | 38.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-09-26 | Initiated | Guggenheim | Buy |
| Dec-05-25 | Resumed | Stifel | Buy |
| Dec-12-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Aug-30-23 | Resumed | B. Riley Securities | Buy |
| Dec-22-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-12-22 | Initiated | Piper Sandler | Overweight |
| Dec-23-19 | Initiated | Oppenheimer | Outperform |
| Dec-18-19 | Initiated | ROTH Capital | Buy |
| Dec-09-19 | Upgrade | Citigroup | Neutral → Buy |
| Dec-05-19 | Initiated | B. Riley FBR | Buy |
| Jun-07-19 | Initiated | Stifel | Buy |
| Jun-05-19 | Initiated | Cowen | Outperform |
View All
X 4 Pharmaceuticals Inc Stock (XFOR) Latest News
Form 4 ARS Pharmaceuticals Inc For: 26 June By Investing.com - Investing.com Nigeria
Cadrenal Therapeutics (CVKD) CEO Quang Pham sells 11,156 shares under 10b5-1 plan - Stock Titan
Form 4 Ionis Pharmaceuticals Inc For: 26 June By Investing.com - Investing.com South Africa
BVF group sells 1,630,658 Kymera (KYMR) shares in joint Form 4 - Stock Titan
Form 144 IONIS PHARMACEUTICALS INC For: 26 June By Investing.com - Investing.com Canada
ARS Pharmaceuticals (NASDAQ: SPRY) grants 30,000 options to RA Capital-linked director - Stock Titan
Director Rajeev Dadoo granted 30,000 ARS Pharmaceuticals (SPRY) stock options - Stock Titan
ARS Pharmaceuticals (SPRY) director Laura Shawver receives 30,000 stock options award - Stock Titan
ARS Pharmaceuticals (SPRY) director Saqib Islam granted 30,000 stock options at $10.54 - Stock Titan
Universe Pharmaceuticals (NASDAQ: UPC) to acquire Best Praise in US$10.75M all-share patent deal - Stock Titan
Universe Pharmaceuticals bets $10.8M on five China patents - Stock Titan
[144] ACADIA PHARMACEUTICALS INC SEC Filing - Stock Titan
Form DEF 14A Amneal Pharmaceuticals Inc Class A For: 26 June - Investing.com Canada
X4 Pharmaceuticals updates investor plans, shares remain thinly traded on Nasdaq - Ad-hoc-news.de
DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP - Medianet News Hub
EU regulator backs Acadia's DAYBU for Rett syndrome - Stock Titan
48Q0 Forecast — Price Target — Prediction for 2027 - TradingView
X4 Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:XFOR) - TradingView
A3E4QR Forecast — Price Target — Prediction for 2027 - TradingView
Form 4 Rhythm Pharmaceuticals Inc For: 25 June By Investing.com - Investing.com Canada
X4 Pharmaceuticals, Thursday trading bias in shares - Ad-hoc-news.de
Form 4 Rigel Pharmaceuticals Inc For: 24 June By Investing.com - Investing.com Canada
TRYNGOLZA® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG) - Business Wire
X4 Pharmaceuticals Inc (XFOR) Institutional Confidence - TradingKey
Layoff Tracker: ADC Therapeutics lays off 17% of global workforce - BioSpace
Form 4 Olema Pharmaceuticals Inc For: 23 June By Investing.com - Investing.com Canada
Form 8K Enanta Pharmaceuticals Inc For: 23 June By Investing.com - Investing.com Canada
Form 4 Atea Pharmaceuticals Inc For: 23 June By Investing.com - Investing.com Canada
Xenon Pharmaceuticals Stock Gains 22% in Six Months: Here's Why - TradingView
Form 8K Armata Pharmaceuticals Inc For: 23 June By Investing.com - Investing.com Canada
Form 8K Elite Pharma Inc For: 23 June By Investing.com - Investing.com Canada
Form 4 Crinetics Pharmaceuticals Inc For: 22 June By Investing.com - Investing.com Nigeria
Form 4 Recursion Pharmaceuticals Inc For: 22 June By Investing.com - Investing.com South Africa
Form 8K Atea Pharmaceuticals Inc For: 22 June By Investing.com - Investing.com Canada
Form 8K Crinetics Pharmaceuticals Inc For: 22 June By Investing.com - Investing.com Canada
Antengene Announces Exclusive License Agreement with MPM BioImpact-Established K2 Therapeutics for ATG-106 and Option for Undisclosed Bispecific TCE - PR Newswire
X4 Pharmaceuticals Inc (XFOR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
X4 Pharmaceuticals Inc (XFOR) Valuation: PE, PB & Fair Value Analysis - TradingKey
X4 Pharmaceuticals Inc (XFOR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
X4 Pharmaceuticals Inc (XFOR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
X4 Pharmaceuticals Inc (XFOR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Crinetics (CRNX) director sells 6,900 shares under 10b5-1 trading plan - Stock Titan
X4 Pharmaceuticals Inc (XFOR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
X4 Pharmaceuticals Inc (XFOR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
X4 Pharmaceuticals Inc (XFOR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
[Form 4] Tarsus Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
FDA Recalls and Warnings: Gas-X Contaminated With Coolant; More Generic Cymbalta Cancer Risks, Supplements Linked to Salmonella Outbreak - MedShadow Foundation
ALERT: NAFDAC warns Nigerians against contaminated children’s drug recalled in US - TheCable
[Form 4] ARS Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Director-linked funds trim Ligand (LGND) stake with 5,000-share sale - Stock Titan
KalVista (NASDAQ: KALV) director options cashed out, canceled in Chiesi deal - Stock Titan
X 4 Pharmaceuticals Inc Stock (XFOR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):